Composition comprising PIC for treatment of cancer
The present disclosure relates to a composition comprising PIC for treatment of cancer. More particularly, the present disclosure discloses a composition for treatment of cancer comprising polyinosinic-polycytidylic acid, an antibiotic or polyamine compound, a positive ion, and optionally a virus, and the use thereof in manufacture of a medicament for treatment of cancer. No figure for publication.
1. A method for treatment of lung cancer in a subject, comprising administering to the subject a composition comprising:
a) polyinosinic-polycytidylic acid (PIC),
b) an antibiotic or a polyamine compound,
c) a cation selected from the group consisting of calcium, cadmium, lithium, magnesium, cerium, cesium, chromium, cobalt, deuterium, gallium, iodine, iron, zinc, and any combination thereof, and
d) a virus;
wherein the virus is inactivated and is incapable of replication in a human subject.
2. The method of claim 1 , wherein the virus belongs to a family selected from the group consisting of rhabdoviridae, adeniviridae, arenaviridae, astroviridae, bunyaviridae, cliciviridae, flaviviridae, hepatitis delta virus, hepeviridae, mononegavi rales, nidovirales, piconaviridae, orthomyxoviridae, papillomaviridae, parvoviridae, polyomaviridae, poxviridae, reoviridae, retroviridae, and togaviridae.
3. The method of claim 2 , wherein the virus belongs to Lyssavirus genus of rhabdoviridae family.
4. The method of claim 3 , wherein the virus is a rabies virus.
5. The method of claim 1 , wherein the antibiotic is selected from the group consisting of kanamycin, tacrolamycin, anthracycline, butyrin sulphate, gentamicin, hygromycin, amikacin, nebramycin, β-lactam, neomycin, puromycin, streptomycin, streptozocin, and any combination thereof.
6. The method of claim 1 , wherein the composition comprises a polyamine compound, wherein the polyamine compound is selected from the group consisting of arginine salt, spermidine, N-(3-aminopropyl), N-(3-aminopropyl)-1, 4-butanediamine, spermine, OS-dimethylaminothiophosphate, poly-lysine, aminoglycoside, and any combination thereof.
7. The method of claim 1 , wherein the route of said administration is selected from the group consisting of intramuscular, intraperitoneal, intravenous, subcutaneous, transdermal, intradermal, intranasal, intraocular, oral, sublingual, intratumoral, and peritumoral.
8. The method of claim 1 , further comprising treating the subject with an anti-tumor treatment regimen is selected from the group consisting of chemotherapy, radiotherapy, targeted therapy, and immunotherapy.
9. The method of claim 1 , wherein the ratio of the virus to the PIC is selected from the group consisting of: 1 IU/50 μg, 1 IU/60 μg, 1 IU 70 μg, 1 IU/80 μg, 1 IU/90 μg, 1 IU/100 μg, 1 IU/125 μg, 1 IU/200 μg, 1 IU/250 μg, 1 IU/300 μg, 1 IU/350 μg, I IU/400 μg, 1 IU/450 μg, 1 IU/500 μg, 1 IU/550 μg, 1 IU/600 μg, 1 IU/700 μg, 1 IU/800 μg, 1 IU/1000 μg, 1 IU/1500 μg, 1 IU/2000 μg, 1 IU/2500 μg, 1 IU/3000 μg, I IU/4000 μg, 1 IU/5000 μg, 1 IU/6000 μg, 1 IU/7000 μg, 1 IU/8000 μg, 1 IU/9000 μg, 1 IU/10,000 μg, and a range between any two of the above ratios.
10. The method of claim 1 , wherein the ratio of the virus to the PIC 1 IU/500 μg.
11. The method of claim 1 , wherein amount of the PIC is between from 250 μg to 5000 μg per unit dose.
12. The method of claim 1 , wherein amount of the PIC is selected from the group consisting of 250 μg, 500 μg, 1000 μg, 1500 μs, 2000 μg, 3000 μg, 4000 μg, and 5000 μg per unit dose.
13. The method of claim 1 , wherein the amount of the virus is selected from the group consisting of 0.5 IU, 1.0 IU, 1.5 IU, 2.0 IU, 2.5 IU, 3.0 IU, 3.5 IU, 4.0 IU, 5.0 IU, 6.0 IU, 7.0 IU, 8.0 IU, 9.0 IU, 10.0 IU, 15.0 IU, 20.0 IU, 30.0 IU, 40.0 IU, 50.0 IU, 60.0 IU, 70.0 IU, 80.0 IU, 90.0 IU, 100.0 IU per unit dose, and a range between any two of the above amounts.
14. The method of claim 13 , wherein the unit dose is prepared into a volume which is selected from the group consisting of 0.1 ml, 0.15 ml, 0.2 ml, 0.5 ml, 1.0 ml, 1.5 ml, 2.0 ml, 2.5 ml, 3.0 ml, 4.0 ml, 5.0 ml, 10.0 ml, 20.0 ml, 30.0 ml, 40.0 ml, 50.0 ml, 60.0 ml, 70.0 ml, 80.0 ml, 90.0 ml, 100.0 ml, 150.0 ml, 200.0 ml, 250.0 ml, and a range between any two of the above volumes.
15. The method of claim 1 , wherein the composition comprises an antibiotic, wherein the antibiotic is kanamycin.
16. The method of claim 15 , wherein the virus is a rabies virus.
17. The method of claim 16 , wherein the cation is calcium.
18. The method of claim 17 , wherein the amount of the rabies virus is between from 1.0 IU to 5.0 IU per unit dose.
19. The method of claim 18 , wherein the amount of PIC is 500 μg to 1000 μg per unit dose.